Lexicon Pharmaceuticals
LXRX
106 hedge funds and large institutions have $280M invested in Lexicon Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 31 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
36% more capital invested
Capital invested by funds: $206M → $280M (+$74M)
25% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 24
10% more call options, than puts
Call options by funds: $522K | Put options by funds: $476K
2.42% less ownership
Funds ownership: 77.08% → 74.66% (-2.4%)
5% less funds holding
Funds holding: 112 → 106 (-6)
19% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$5.28M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$932K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$928K |
| 4 |
Morgan Stanley
New York
|
+$806K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$803K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.29M |
| 2 |
Millennium Management
New York
|
-$2.68M |
| 3 |
OCA
Octagon Capital Advisors
New York
|
-$2.1M |
| 4 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$1.24M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$555K |
LXRX Hedge Fund Activity: Q4 2023 in Review
106 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2023, worth a combined $280M — up 36% from $206M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of LXRX and 25 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 30 added.
The largest buyer was BVF Inc, adding an estimated $5.28M. The largest seller was Fidelity Investments, cutting an estimated $6.29M.
- 106 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2023, down from 112 in Q3 2023.
- Funds reported $280M of Lexicon Pharmaceuticals stock for Q4 2023, up 36% quarter-over-quarter.
- 25 funds opened new Lexicon Pharmaceuticals positions in Q4 2023 and 31 closed out, a net change of -6 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2023 was BVF Inc, an estimated $5.28M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2023 was Fidelity Investments, an estimated $6.29M sold.
Based on aggregated 13F filings for Q4 2023.